Get the Daily Brief
Latest Biotech News
AstraZeneca’s oral GLP-1 accelerates obesity competition
AstraZeneca is pressing into the oral obesity market with elecoglipron, positioning for later-stage studies after two Phase 2 readouts presented at the ADA meeting. The company is aiming to secure...
Clinical and regulatory momentum in precision diagnostics and MRD
Personalis secured CE-IVD marking for its EDTA and cfDNA blood collection kits in Europe under the EU IVDR framework. The kits are intended to standardize the pre-analytical phase for NeXT...
Incyte and other firms expand through precision hematology acquisitions
Incyte’s Vega deal is the latest in a series of late-stage strategy moves aimed at extending its hematology platform beyond near-term patent cliffs. VGA-039 is in Phase III development for von...
Precision oncology imaging and single-cell pharmacobiology
A new Nature Biotechnology approach, single-cell spatial pharmacobiology (SSP), mapped how systemically infused therapeutic antibodies behave inside patient tumors at single-cell resolution....
City Therapeutics raises for RNAi clinic expansion
City Therapeutics collected $99.5 million to advance clinical development for its first three RNAi candidates and extend the platform to targets beyond the liver. The fundraising comes as...
Regulatory access for gene sequencing specimens and trial scaling
Recent CE-IVD and coverage steps for specimen handling and MRD testing reflect an industry push to reduce operational friction in oncology trials. Personalis’ CE-IVD marking for blood collection...
Big data for AI-driven genomics consortium
Google DeepMind and the Wellcome Sanger Institute launched an AI genomics consortium aimed at building large genomic datasets for training predictive biology models. Google.org and Google DeepMind...
AstraZeneca’s obesity pill data and discontinuation optics
Boehringer Ingelheim’s survodutide continued to draw scrutiny in obesity as Phase 3 updates were presented around tolerability, including discontinuation rates. ADA26 coverage pointed to patient...
FDA and trade policy uncertainty for pharma manufacturing inputs
A new U.S. Federal Register notice outlined how manufacturers can apply for company-specific “onshoring agreements” to reduce Section 232 pharmaceutical tariff burdens, but key eligibility...
GSK’s Nuvalent buyout targets FDA decisions for two lung cancer drugs
GSK agreed to acquire Nuvalent for $10.6 billion, buying two experimental lung cancer therapies that are under FDA review with decision timelines later this year. The deal underscores how Big...
Incyte expands hematology reach with Vega’s late-stage von Willebrand candidate
Incyte is buying Vega Therapeutics’ subsidiary Star Therapeutics’ Vega unit in a $1.25 billion upfront package, targeting a late-stage von Willebrand disease (VWD) candidate in Phase III...
Nurix-Roche alliance puts a BTK degrader on course against Lilly’s Jaypirca
Roche agreed to pay Nurix Therapeutics $700 million upfront to co-develop and co-commercialize bexobrutideg, an oral BTK degrader that Roche believes could take share in B-cell malignancies. The...
Incyte and J&J further escalate oncology dealmaking with Vega and Firefly
Two major transactions reinforced a broader 2026 pattern of Big Pharma paying for late-stage or near-late-stage oncology and immunotherapy platforms. In one deal stream, Incyte’s Vega acquisition...
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer
Tango reported early clinical results showing its PRMT5 inhibitor vopimetostat may add to daraxonrasib activity in metastatic pancreatic ductal adenocarcinoma, lifting the response profile in a...
Treeline to go public via reverse merger with Standard BioTools
Treeline Biosciences announced plans to enter public markets through an all-stock reverse merger with Standard BioTools, combining precision oncology capabilities with Treeline’s oncology...
City Therapeutics raises ~$100M series B to push RNAi candidates
City Therapeutics raised $99.5 million in a Series B financing to expand development of three RNAi candidates and to broaden beyond initial liver-focused targets. The startup—built by former...
Amphista gains FDA IND clearance for BRD9 degrader in AML
Amphista Therapeutics received FDA IND clearance for AMX-883, an orally bioavailable degrader of BRD9 intended for acute myeloid leukemia (AML). The company expects to start a Phase I trial in...
AI genomics consortium launched by DeepMind and Wellcome Sanger
Google DeepMind and the Wellcome Sanger Institute launched an AI genomics consortium to build large genomic datasets intended to train predictive biological machine learning models. Google.org...
VolitionRx prices a $4.6M public offering
VolitionRx priced a public offering of common stock and warrants that could raise gross proceeds of $4.6 million, with additional proceeds possible if warrants are fully exercised. The company...
Regulatory and approvals - oncology small molecule
FDA approved sonrotoclax (Beqalzi), a Bcl-2 inhibitor, in May 2026 for mantle cell lymphoma patients who have tried at least two prior therapies, positioning the drug as the second Bcl-2 inhibitor...